Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Interventions: Arm A:tislelizumab combined with cetuximab and irinotecan Primary outcome(s): Overall response rate (ORR) Study Design: Single arm
创建时间：
2021-01-15
